Project Title

A study comparing Talquetamab plus Pomalidomide, Talquetamab plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in participants with relapsed or refractory myeloma who have received an anti-CD38 antibody and Lenalidomide (MonumenTAL-6)

Official Title

A phase 3 randomized study comparing Talquetamab in combination with pomalidomide (Tal-P), Talquetamab in combination with Teclistamab (Tal-Tec), and investigator's choice of either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in participants with relapsed or refractory myeloma who have received 1 to 4 prior lines of therapy including an anti-CD38 antibody and Lenalidomide.

Project Summary

The purpose of this study is to compare the effectiveness of either Talquetamab plus Pomalidomide (Tal-P) or Talquetamab plus Teclistamab (Tal-Tec) with Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd).

Blood Disorder

  • Relapsed or refractory multiple myeloma

Patient Recruitment Details

Patient recruitment status: recruiting

Number of patients (Globally)

795